A legal battle has erupted in the pharmaceutical industry, with a major player taking on a telehealth provider. Novo Nordisk, the maker of the popular weight-loss drug Wegovy, has filed a lawsuit against Hims & Hers, alleging patent infringement and deceptive practices.
But here's where it gets controversial: Hims & Hers had recently launched a $49 weight-loss pill, claiming it was a compounded version of Novo's Wegovy. This move sparked immediate backlash, with the FDA threatening action and Hims & Hers halting sales just days later.
Novo Nordisk's drug, semaglutide, is the only GLP-1 drug approved as a pill for weight loss. It's a blockbuster medication, also sold under the brand Ozempic for Type 2 diabetes. So, when Hims & Hers announced their cheaper alternative, it raised some serious red flags.
John Kuckelman, Novo's senior vice president and group general counsel, stated that Hims & Hers is "mass marketing unapproved knock-off versions of Wegovy and Ozempic, evading the FDA's rigorous review process." He added, "This is not only dangerous and deceptive to patients but also undermines the scientific integrity of these treatments."
And this is the part most people miss: Novo claims that Hims & Hers is also compounding injectable versions of their FDA-approved medications, putting patient health at risk. Hims & Hers has not yet responded to these allegations.
The FDA has allowed compounding pharmacies to create drug copies during shortages, but the semaglutide shortage was declared over in February 2025. Now, the FDA plans to restrict GLP-1 ingredients used in compounded drugs, citing quality, safety, and efficacy concerns.
So, is this a case of a big pharma company protecting its turf, or a necessary move to safeguard patient health? What do you think? Feel free to share your thoughts in the comments below!
